To determine the cost-effectiveness of prenatal iron supplementation and misoprostol use as interventions to prevent maternal mortality in home births in rural India.
A cost-effectiveness analysis depicted three hypothetical cohorts of 10 000 pregnant women delivering at home in rural India: one with no intervention, one receiving standard prenatal iron supplements, and 1 receiving 600 µg of misoprostol in the third stage of labor.
Misoprostol used to prevent postpartum hemorrhage resulted in a 38% (95% CI, 5%–73%) decrease in maternal deaths, while prenatal iron supplementation resulted in a 5% (95% CI, 0%–47%) decrease. Misoprostol cost a median US $1401 (IQR US $1008–$1848) prenatal iron supplementation cost a median US $2241 (IQR No Lives Saved–$3882) per life saved compared with the standard care outcome.
Misoprostol is a cost-effective maternal mortality intervention for home births. Iron supplementation may be worthwhile to improve women's health, but it is uncertain whether it can prevent mortality after hemorrhage.